Prevalence and clinical profile of inflammatory bowel disease patients with small bowel cancer: A retrospective analysis of National Inpatient Sample data.

484 Background: Small bowel cancer (SBC) accounts for around 3% of all gastrointestinal malignancies, with inflammatory bowel disease(IBD) recognized as a risk factor. Our study aims to evaluate the IBD prevalence in SBC patients, annual trends, and associated demographics, comorbidities, and healthcare burden. Methods: Adults(≥18 years) with SBC were queried from the National Inpatient Sample(NIS 2016-2022). The presence of IBD was further identified via prevalidated ICD-10 codes. We estimated the prevalence of IBD among SBC patients along with the yearly trend. Baseline patient demography and comorbidities were compared among both IBD and non-IBD cohorts. All analyses were performed via STATA 18.0, adjusting for the stratification, cluster, and weight of the NIS. Results: We found 67345 SBC patients which included 2360 cases(3.5%) of IBD, of which 83.47% had Crohn’s disease (CD) and 16.53% had ulcerative colitis (UC). The highest annual prevalence was noted in 2019 (4.21%), with a nadir in 2021 (2.9%). Yearly trends fluctuated as illustrated in Table 1 and were not statistically significant (ptrend = 0.229). IBD patients were younger (mean age 62.37 vs 66.81 years, p =